use of intensive chemotherapy, the incidence of therapyrelated MDS is rising. [4] [5] [6] [7] There are also recent reports of therapy-related MDS occurring after autologous transplants Therapy-related myelodysplasia (MDS) is a fatal marrow disorder distinct from primary MDS. We examined for lymphoma and breast cancer.
12,13
cyclophosphamide/total body irradiation, with and without cytosine arabinoside, busulfan/cyclophosTreatment for therapy-related MDS has included intensive induction therapy similar to the regimens used for phamide, and cyclophosphamide/etoposide/carmustine. For patients with therapy-related MDS, the median age acute myelogenous leukemia. These regimens have induced a remission in 60% of patients but the remission duration is was 32 years and the actuarial disease-free survival was 24% (95% confidence interval 6, 42%) with a median only a few months and the overall survival is poor. [14] [15] [16] Other approaches have included retinoids, 5-azacytidine, cytosine follow-up of 3 years. For patients with primary MDS, the median age was 36 years and the actuarial diseasearabinoside, growth factors, and hormonal agents, all with no improvement in survival.
738 Table 2 Bone marrow transplant a One received oral 32 P. RA = refractory anemia; RARS = refractory anemia with ringed sideroTherapyPrimary blasts; RAEB = refractory anemia with excess blasts; RAEB-IT = refracrelated n = 25 tory anemia with excess blasts in transformation; AML = acute myeloid n = 18 leukemia; CMF = cyclophosphamide, methotrexate, 5-FU; MOPP = nitrogen mustard, vincristine, procarbazine, prednisone. Figure 1 . The median time g/m 2 twice a day for 3 days or 500 mg/m 2 twice a day for to engraftment (Ͼ500 granulocytes/l) was 20 days (range 3 days) followed by cyclophosphamide (1800 mg/m 2 /day 14-30 days). Graft failure occurred in one recipient of a T for 2 days), and fractionated total body irradiation (TBI) cell-depleted bone marrow who received two subsequent 1200-1400 cGy administered in six to eight doses at 5-10 transplants and eventually died of adult respiratory distress cGy/min from opposing anteroposterior/posteroanterior 4 syndrome (ARDS). Four patients relapsed and died of MeV linear accelerators. One patient received cyclophosrecurrent disease (Table 3 ). The 13 patients who received phamide 1800 mg/m 2 /day for 2 days and TBI 1200 cGy. a transplant from an HLA-matched sibling had an actuarial Those patients who had received mediastinal or abdominal disease-free survival of 27% at 3 years. radiation therapy in the past were conditioned with chemoAcute GVHD was considered assessable if the patient therapy alone. Six therapy-related patients and one primary had engrafted by 30 days, and chronic GVHD was assessed patient received busulfan 4 mg/kg/day for 4 days followed if there was sustained engraftment at Ͼ100 included veno-occlusive disease (VOD) of the liver in two Prophylaxis for GVHD was administered according to patients and ARDS, pneumocystis pneumonia, aspergillus, active protocols at the time of treatment (Table 2) . Methoand cytoxan cardiomyopathy in one patient each. Overall, trexate (10 or 15 mg/m 2 /day on days 1, and 10 mg/m 2 /day regimen-related toxicity resulted in six deaths in the 18 on days 3, 6 and 11 or 10 mg/m 2 /day on days 1, 8, 15, 22 patients (33%). Including the two deaths from GVHD and and 29) plus cyclosporine were administered to 25 patients. the one death from graft failure, the transplant-related Three of the four recipients of unrelated donor transplants mortality was 50% (nine of 18 patients). also received solumedrol 3 mg/kg/day as part of their GVHD prophylaxis. Five patients received methotrexate alone 10 mg/m 2 on days 1, 3, 6 and 11. One patient received FK506 alone. Seven patients had marrows purged of T cells with anti-CD5 monoclonal antibodies -either anti-Leu-1 (Becton Dickinson, Mountain View, CA, USA) plus baby rabbit complement or ST 1 immunotoxin (ST1 immunotoxin, Sanofi Research, Montpelier, France) conjugated to ricin A chain. 34 These patients did not receive any pharmacologic GVHD prophylaxis. No GVHD prophylaxis was given to the syngeneic transplants. All patients were nursed in laminar air flow rooms and received low bacteria diets and gut decontamination. Patients were evaluated for GVHD by an attending physician and GVHD was graded according to standard criteria. 35 
Statistics
The outcomes measured in this study were overall survival, relapse rate, and treatment-related toxicity. Disease-free fidence limits were calculated according to the formula of 740 ling donor, had a better survival rate than those without a fully matched sibling donor (relative risk 11.8, P = 0.003).
Patients younger than 30 had a better survival rate than older patients (relative risk 4.6, P = 0.02). Relative risk Primary MDS estimates for FAB subtypes and cytogenetics did not reach statistical significance in the four-factor multivariate analyTen of the 25 patients are alive with a median follow-up of 4 years (range 1.0-12 years) Nine of these 10 patients sis. A good risk group of patients less than age 30 and with FAB subtypes refractory anemia, refractory anemia with are disease-free for an actuarial disease-free survival at 3 years of 43% (95% confidence interval 22, 64%) (Figure ringed sideroblasts, and a fully matched sibling donor had a better survival rate. However, only six patients fell into 1). The median time to engraftment (Ͼ500 granulocytes/l) was 20 days (range 15-28 days). Graft failure occurred in this good risk group. We have analyzed our data separating the MDS patients two patients who received second transplants and eventually succumbed to infection. Both patients had increased from those patients who had already transformed to AML. The survival experience was not different (log-rank test P fibrosis in their marrow and received T cell-depleted transplants. Two patients have relapsed, one of whom has died. = 0.98) among the three groups that included primary MDS, therapy-related MDS and AML patients. Two patients Those patients (21 patients) who received a transplant from an HLA-matched sibling had an actuarial disease-free surdeveloped AML post-primary MDS and received successful induction chemotherapy. One of these patients died of vival of 47% at 3 years.
Acute GVHD grades 2-4 occurred in nine patients and relapse disease and the other is alive with chronic GVHD. We have previously reported that patients with marrow was the cause of death in three patients. Chronic GVHD occurred in three patients. Death was attributed to chronic fibrosis and T cell depletion had a high incidence of graft failure. 27 Fourteen patients had evidence of marrow GVHD in two patients. Other causes of death included two cases each of cytomegalovirus (CMV) pneumonia, ARDS, fibrosis; nine were in the primary MDS group. Three patients -two with primary MDS and one with therapyand invasive fungal infections, and one case each of VOD and bowel necrosis. Thus, regimen-related toxicity resulted related MDS -experienced graft failure. All three patients received T cell-depleted transplants and two of the three in eight deaths in 25 patients (31%). Including the five patients who died of GVHD and the two patients who died also had marrow fibrosis (Table 4) . Although the type of GVHD prophylaxis did not affect overall survival (P = of graft failure, the transplant-related mortality was 60% (15 of 25 patients).
0.54), T cell depletion was highly predictive for graft failure (P = 0.006). Two of 14 patients with marrow fibrosis We compared the outcomes between patients with therapy-related MDS and primary MDS. The difference in surhad graft failure; one of 29 patients without marrow fibrosis had graft failure. vival rates between the two groups did not reach statistical significance (P = 0.42). The relapse rate was 22% (four of 18 patients) for patients with therapy-related MDS and 8% Table 4 Effect of T cell depletion on graft failure (two of 25 patients) for patients with primary MDS. This difference also did not reach statistical significance (P =
GVHD prophylaxis Graft No graft
0.38). There was no difference in regimen-related toxicity failure failure between the two group of patients (31 vs 33%, P = 0.77). However, the small number of patients treated made it dif-T cell depletion 3 4 ficult to detect small differences.
Pharmacologic prophylaxis 0 36
We combined data from both therapy-related and the pri-
mary MDS patients to study the effect of various prognostic P value by Fisher's exact test.
factors on outcome. In univariate analyses, the differences Discussion in three of these patients. Two of the six patients who had received prior cytotoxic therapy survived the transplant. Although the effectiveness of cytotoxic chemotherapy prior The prognosis for therapy-related MDS is poor, with survival of only a few months. Consequently, allogeneic BMT to transplant on the outcome of transplant cannot be judged adequately from this study, pre-transplant chemotherapy has been offered to patients with therapy-related as well as primary MDS. 15, [26] [27] [28] [29] [30] 39 The appropriate timing, conditionmay not be necessary to achieve a remission and may only delay the transplant. ing regimen, and GVHD prophylaxis for transplantation of these patients is uncertain, and there has not been an Patients who received a T cell-depleted transplant had a higher risk of graft failure. We and others have shown that organized effort to determine the optimal therapy. Most survival data include mixtures of therapy-related and primary T cell-depleted transplants demonstrate a higher risk of graft failure in patients with MDS compared to patients MDS.
26, 40 Our study represents the largest single-institution collection of therapy-related patients that are compared with leukemia. 34, 41, 44 Thus, our data would indicate that pharmacologic GVHD prophylaxis may be safer for this directly to patients with primary MDS. We have shown here that bone marrow transplantation is a curative progroup of patients. No patients who received pharmacologic GVHD prophylaxis experienced graft failure, including 12 cedure for patients with therapy-related MDS. There was some difference in the outcome of the therapy-related as patients with marrow fibrosis. The Seattle group has recently shown that fibrosis had no effect on engraftment compared with the primary MDS patients. However, this observed difference did not attain statistical significance, rates. 45 The optimal conditioning regimen for these patients perhaps due to the small number of subjects in this study. Four patients with therapy-related MDS and two patients remains unknown. 46 In this study, 32 patients were conditioned with a TBI containing regimen. Those patients with primary MDS relapsed; the four therapy-related patients and one of the two primary MDS patients have who had received radiation therapy in the past were conditioned with a chemotherapy-only conditioning regimen, died of relapsed disease. This difference also did not reach statistical significance. Cytogenetics had no predictive sigeither busulfan/cyclophosphamide or cyclophosphamide/ BCNU/etoposide (CBV). Although the size of our study nificance in this study, perhaps due to the small number of patients. and the differences between the TBI and chemotherapy only groups did not permit a direct comparison of conIn our earlier reports, we found that patients with therapy-related MDS had a higher regimen-related toxicity than ditioning regimens, three of the 10 therapy-related patients who were conditioned with chemotherapy alone are alive. patients with primary MDS.
27, 41 We postulated that this difference might be related to the toxicity of prior therapy. In
The efficacy of the busulfan/ cyclophosphamide regimen for patients with myelodysplasia was recently shown.
47,48
our current study, with more than twice the number of patients, this difference was not significant (33% for therCyclophosphamide alone is ineffective; thus either busulfan or BCNU and etoposide must be added to the conditionapy-related vs 31% for primary). The transplant-related mortality, which also includes deaths from GVHD and graft ing regimen.
49
Allogeneic transplants have traditionally been limited to failure, was high for both groups, 50% for the therapyrelated MDS patients and 60% for the primary MDS young patients with an HLA-matched sibling donor. However, only 30% of patients would be estimated to have a patients. The two groups did not receive the same preparative regimens; more patients in the therapy-related MDS matched sibling to serve as donor. Therefore, the use of unrelated donors has been increasingly important. Two prigroup were conditioned without TBI, as they had received prior radiation treatment for their initial disease. Because mary MDS patients and two therapy-related MDS patients received unrelated donor transplants; two of these four this is a retrospective study over many years of a relatively uncommon disease, patients were treated with different transplants were from a single antigen-mismatched unrelated donor, a group that has been shown to have a high conditioning and GVHD prophylactic regimens based on the year of transplant and current protocols active at that mortality. 50 One of these four patients, who had therapyrelated MDS and received a fully matched unrelated donor time. Because of the size of the study it was difficult to determine if the year of transplant had any impact on surtransplant, survived. Owing to the small number of patients, the survival rate for patients who received an unrelated vival. Six therapy-related patients were transplanted after 1990 and three survive; 17 primary MDS patients were donor transplant (n = 4) was not statistically different from the survival rate for those who received a family donor transplanted after 1990 and seven survive.
The transplant-related mortality was 50% in our patients. transplant (n = 39). The National Marrow Donor Program reported 18% disease-free survival in 32 patients with myeThis may represent the intensive conditioning regimen which included Ara-C, in addition to cytoxan/TIB. This lodysplasia who received transplants from unrelated donors; these data included both therapy-related and pritransplant-related mortality is similar to other studies in the literature. O'Donnell et al 23 report 50% transplant-related mary MDS patients. 50 As the number of patients with unrelated donor transplants increases, we may better be able to mortality in their 20 patients, of whom one had therapyrelated MDS. The Seattle group has also shown transplantanalyze prognostic factors in this particular group. Other investigators have reported similar survival rates related mortalities ranging from 36 to 68%. 42 The high transplant-related mortality in MDS is confirmed in a recent for patients with therapy-related MDS undergoing BMT. 15, 23, 25, [28] [29] [30] 39 These studies all confirmed survival report in the literature. 43 Only six of our patients received cytotoxic induction rates ranging from 18 to 50%. 
